Amphastar Pharmaceuticals Total Long Term Liabilities 2012-2024 | AMPH

Amphastar Pharmaceuticals total long term liabilities from 2012 to 2024. Total long term liabilities can be defined as the sum of all non-current liabilities.
Amphastar Pharmaceuticals Annual Total Long Term Liabilities
(Millions of US $)
2023 $648
2022 $118
2021 $122
2020 $70
2019 $69
2018 $42
2017 $50
2016 $38
2015 $35
2014 $45
2013 $22
2012 $24
2011 $
2009 $
Amphastar Pharmaceuticals Quarterly Total Long Term Liabilities
(Millions of US $)
2024-09-30 $658
2024-06-30 $641
2024-03-31 $647
2023-12-31 $648
2023-09-30 $692
2023-06-30 $538
2023-03-31 $119
2022-12-31 $118
2022-09-30 $119
2022-06-30 $121
2022-03-31 $122
2021-12-31 $122
2021-09-30 $124
2021-06-30 $74
2021-03-31 $68
2020-12-31 $70
2020-09-30 $66
2020-06-30 $64
2020-03-31 $66
2019-12-31 $69
2019-09-30 $65
2019-06-30 $68
2019-03-31 $52
2018-12-31 $42
2018-09-30 $43
2018-06-30 $44
2018-03-31 $50
2017-12-31 $50
2017-09-30 $50
2017-06-30 $47
2017-03-31 $37
2016-12-31 $38
2016-09-30 $40
2016-06-30 $35
2016-03-31 $34
2015-12-31 $35
2015-09-30 $41
2015-06-30 $44
2015-03-31 $45
2014-12-31 $45
2014-09-30 $55
2014-06-30 $53
2014-03-31 $21
2013-12-31 $22
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $24
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.142B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Personalis (PSNL) United States $0.239B 0.00
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00